Back on the boards after its wet AMD setback, Opthea is pinning its hopes on a rare lung disease and a new name.
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results